Sutro Biopharma Presents Preclinical Data on ADC Programs at AACR 2026

Sutro Biopharma, a clinical-stage oncology company, presented preclinical data on its pipeline of next-generation antibody drug conjugates (ADCs) at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations included five posters and one oral presentation. The event took place on April 19, 2026.

STRO-004 Preclinical Results In a preclinical study, STRO-004 showed antitumor activity in multiple tissue factor (TF)-expressing solid tumor patient-derived xenograft models.

At a dose of 5 mg/kg, the ADC achieved disease control and tumor reduction across various tumor types. The study compared STRO-004 to benchmark ADCs and noted differences in efficacy. The highest non-severely toxic dose for STRO-004 was 50 mg/kg.

The pharmacokinetic profile indicated potential for increased drug exposure and payload delivery. Sutro Biopharma stated that these findings support expectations for clinical performance.

Company

Statements and Future Plans > "The STRO-004 preclinical data presented today underscore the potential of our next-generation ADCs to drive meaningful activity across multiple solid tumors," said Jane Chung, Sutro's Chief Executive Officer.

The company reported that STRO-004 is advancing in clinical trials. Initial results from a Phase 1 study are anticipated in mid-2026. The data are intended to inform further development across indications.

Background on Sutro

Biopharma Sutro Biopharma focuses on site-specific and novel-format ADCs for oncology.

The company's pipeline includes single and dual-payload ADC programs. These presentations at AACR 2026 highlight ongoing research in this area.